Type 2 diabetes with SSRIs in paediatric patients
- PDF / 170,450 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 10 Downloads / 175 Views
1
Type 2 diabetes with SSRIs in paediatric patients Paediatric patients initiating selective serotonin reuptake inhibitors (SSRIs) in the USA may have a small increased risk of developing type 2 diabetes (T2D), according to study results reported in JAMA Psychiatry, "particularly publicly insured patients". The cohort study included 1582 914 patients, 10–19 years of age, from the publicly-insured MAX database or the privately-insured MarketScan database who had a diagnosis for which SSRIs are indicated. At least two SSRI prescriptions were filled by 316 178 publicly insured patients, who were compared with 632 356 patients who were not receiving treatments with known metabolic adverse events; 211 460 privately insured SSRI recipients were compared with 422 920 controls. Among publicly insured patients, the T2D incidence in those who initiated SSRIs compared with controls in an intent-to-treat analysis was 2.32 vs 1.65 cases per 1000 person-years (PY). After adjustment for baseline covariates, there was a small but significantly increased risk of T2D (adjusted hazard ratio [HR] 1.13; 95% CI 1.04, 1.22). The risk increased with continuous SSRI treatment in the as-treated analysis (1.0 vs 1.8 cases per 1000PY; HR 1.33; 1.21, 1.47), with a number needed to harm (NHM) of 115 for ≥2 years of treatment and 352 for ≥5 years of treatment. Among privately insured patients, the T2D incidence in an intent-to-treat analysis was 0.63 vs 0.54 cases per 1000PY, with no significantly increased risk (HR 1.01; 0.84, 1.23). Similar results occurred in the as-treated analysis (0.48 vs 0.41 cases per 1000PY; HR 1.10; 0.88, 1.36). "This study highlights the opportunities of using RWD [real world data] to generate evidence on drug safety in children and adolescents", note the authors, who add that "patients with high-risk characteristics should be monitored more closely for glucose intolerance". They also note that "when making treatment decisions in young patients, this potential small risk of T2D, along with other potential adverse effects of SSRIs such as nausea and sleep disturbances, should be weighed against the benefits of treating pediatric depression and anxiety disorders". Sun JW, et al. Association of Selective Serotonin Reuptake Inhibitors With the Risk of Type 2 Diabetes in Children and Adolescents. JAMA Psychiatry : 2 Sep 2020. 803501991 Available from: URL: https://doi.org/10.1001/jamapsychiatry.2020.2762
0114-9954/20/1822-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 19 Sep 2020 No. 1822
Data Loading...
